Denali Therapeutics Inc. (DNLI) News
Track canonical SquawkNews coverage tagged to DNLI, Denali Therapeutics Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 3 indexed stories across 2 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
DNLI points to AVYLAH launch for Hunter syndrome and broader pipeline
DNLI says it is leveraging its validated platform and capital base to advance a broad pipeline, highlighted by the AVYLAH launch for Hunter syndrome and multiple enzyme replacement therapies. Clinical and biomarker reado
EQUITY | Sep 09, 2026, 03:36 PM UTC
L
DNLI cites strong AVLAYAH launch and pipeline progress
Denali Therapeutics highlighted a strong AVLAYAH launch, robust pipeline progress, and global expansion plans, with key program data readouts expected in 2027–2028. Strategy centers on a multi-product enzyme franchise an
EQUITY | Sep 09, 2026, 02:41 PM UTC
L
DNLI Unwarranted Selloff in Sympathy to BIIB's Tau ASO for Alzheimer's; raise PT to $35 from $31 @ DBAB
DNLI Unwarranted Selloff in Sympathy to BIIB's Tau ASO for Alzheimer's; raise PT to $35 from $31 @ DBAB
EQUITY | Jul 16, 2026, 12:10 PM UTC